One year af­ter Fetro­ja ap­proval, Sh­iono­gi ex­pands la­bel to in­clude dif­fi­cult-to-treat pneu­mo­nia

A year af­ter snag­ging ap­proval in com­pli­cat­ed uri­nary tract in­fec­tions, Sh­iono­gi’s an­tibi­ot­ic Fetro­ja has added an­oth­er in­di­ca­tion to its la­bel: hos­pi­tal-ac­quired and ven­ti­la­tor-as­so­ci­at­ed bac­te­r­i­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER